Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phytocannabinoids for Chronic Chemotherapy-Induced Peripheral Neuropathy
NCT06731894Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Arm I (CBD), Arm II (THC:CBD) and Arm III (placebo) (3 arms). Primary endpoint: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity. Started Oct 2025; status: recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06731894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731894.